PIVKA-II is a useful tumor marker for recurrent hepatocellular carcinoma after surgical resection

Oncology

Volumn 72, Issue SUPPL. 1, 2007, Pages 52-57

  Kim, Do Young ^a   Paik, Yong Han ^a   Ahn, Sang Hoon ^a   Youn, Young Jun ^a   Choi, Jong Won ^a   Kim, Ja Kyung ^a   Lee, Kwan Sik ^a   Chon, Chae Yoon ^a   Han, Kwang Hyub ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Hepatocellular carcinoma; Prothrombin induced by vitamin K absence or antagonist II

Indexed keywords

ALPHA FETOPROTEIN; DECARBOXYPROTHROMBIN; PROTHROMBIN; TUMOR MARKER;

ADULT; CANCER EPIDEMIOLOGY; CANCER SURGERY; CONFERENCE PAPER; CONTROLLED STUDY; EARLY DIAGNOSIS; FEMALE; FOLLOW UP; HISTOLOGY; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RECURRENT CANCER; SENSITIVITY AND SPECIFICITY; STATISTICAL SIGNIFICANCE; TUMOR RECURRENCE;

ADULT; AGED; ALPHA-FETOPROTEINS; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; EARLY DIAGNOSIS; FEMALE; FOLLOW-UP STUDIES; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; PROTEIN PRECURSORS; PROTHROMBIN; ROC CURVE; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 37149003890     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000111707     Document Type: Conference Paper

References (22)

1. Okuda K: Early recognition of hepatocellular carcinoma. Hepatology 1986;6:729-738.
2. Javadpour N: The role of biologic tumor markers in testicular cancer. Cancer 1980; 45(suppl 7):1755-1761.
3. Cui R, He J, Zhang F, Wang B, Ding H, Shen H, Li Y, Chen X: Diagnostic value of protein induced by vitamin K absence (PIVKAII) and hepatoma-specific band of serum gamma-glutamyl transferase (GGTII) as hepatocellular carcinoma markers complementary to α-fetoprotein. Br J Cancer 2003;88:1878-1882.
4. Liebman HA, Furie BC, Tong MJ, Blanchard RA, Lo KJ, Lee SD, Coleman MS, Furie B: Des-γ-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. N Engl J Med 1984;310:1427-1431.
5. Fujiyama S, Izuno K, Gohshi K, Shibata J, Sato T: Clinical usefulness of des-gamma-carboxy prothrombin assay in early diagnosis of hepatocellular carcinoma. Dig Dis Sci 1991;36:1787-1792.
6. Aoyagi Y, Oguro M, Yanagi M, Mita Y, Suda T, Suzuki Y, Hata K, Ichii K, Asakura H: Clinical significance of simultaneous determinations of alpha-fetoprotein and des-gamma-carboxy prothrombin in monitoring recurrence in patients with hepatocellular carcinoma. Cancer 1996;77:1781-1786.
7. Volk ML, Hernandez JC, Su GL, Lok AS, Marrero JA: Risk factors for hepatocellular carcinoma may impair the performance of biomarkers: A comparison of AFP, DCP, and AFP-L3. Cancer Biomarkers 2007:79-87.
8. Kasahara A, Hayashi N, Fusamoto H, Kawada Y, Imai Y, Yamamoto H, Hayashi E, Ogihara T, Kamada T: Clinical evaluation of plasma des-γ-carboxy prothrombin as a marker protein of hepatocellular carcinoma in patients with tumors of various sizes. Dig Dis Sci 1993;38:2170-2176.
9. Suehiro T, Matsumura T, Itasaka H, Taketomi A, Yamamoto K, Sugimachi K: Des-gamma-carboxy prothrombin and proliferative activity of hepatocellular carcinoma. Surgery 1995;117:682-691.
10. Fujiyama S, Morishita T, Sagara K, Motohara K, Matsuda I: Clinical evaluation of plasma abnormal prothrombin (PIVKA-II) in patients with hepatocellular carcinoma. Hepatogastroenterology 1986;33:201-205.
11. Fujiyama S, Morishita T, Hashiguchi O, Sato T: Plasma abnormal prothrombin (des-gamma-carboxy prothrombin) as a marker of hepatocellular carcinoma. Cancer 1988;61:1621-1628.
12. Kim JK, Han KH, Lee JT, Paik YH, Ahn SH, Lee JD, Lee KS, Chon CY, Moon YM: Long-term clinical outcome of phase IIb clinical trial of percutaneous injection with holmium-166/chitosan complex (Milican) for the treatment of small hepatocellular carcinoma. Clin Cancer Res 2006;12:543-548.
13. Tsai SL, Huang GT, Yang PM, Sheu JC, Sung JL, Chen DS: Plasma des-gamma-carboxy-prothrombin in the early stage of hepatocellular carcinoma. Hepatology 1990;11:481-488.
14. Grazi GL, Mazziotti A, Legnani C, Jovine E, Miniero R, Gallucci A, Palareti G, Gozzetti G: The role of tumor markers in the diagnosis of hepatocellular carcinoma, with special reference to the des-gamma-carboxy prothrombin. Liver Transplant Surg 1995;1:249-255.
15. Ishii M, Gama H, Chida N, Ueno Y, Shinzawa H, Takagi T, Toyota T, Takahashi T, Kasukawa R: Simultaneous measurements of serum alpha-fetoprotein and protein induced by vitamin K absence or for detecting hepatocellular carcinoma. South Tohoku District Study Group. Am J Gastroenterol 2000;95:1036-1040.
16. Nakamura S, Nouso K, Sakaguchi K, Ito YM, Ohashi Y, Kobayashi Y, Toshikuni N, Tanaka H, Miyake Y, Matsumoto E: Sensitivity and specificity of des-gamma-carboxy prothrombin for diagnosis of patients with hepatocellular carcinomas varies according to tumor size. Am J Gastroenterol 2006;101:2038-2043.
17. Marrero JA, Su GL, Wei W, Emick D, Conjeevaram HS, Fontana RJ, Lok AS: Des-gamma-carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in American patients. Hepatology 2003;37:1114-1121.
18. Llovet JM, Schwartz M, Mazzaferro V: Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis 2005;25:181-200.
19. Cha C, Fong Y, Jarnagin WR, Blumgart LH, DeMatteo RP: Predictors and patterns of recurrence after resection of hepatocellular carcinoma. J Am Coll Surg 2003;197:753-758.
20. Pawlik TM, Poon RT, Abdalla EK, Zorzi D, Ikai I, Curley SA, Nagomey DM, Belghiti J, Ng IO, Yamaoka Y, Lauwers GY, Vauthey JN: International Cooperative Study Group on Hepatocellular Carcinoma. Critical appraisal of the clinical and pathologic predictors of survival after resection of large hepatocellular carcinoma. Arch Surg 2005;140:450-457.
21. Shah SA, Cleary SP, Wei AC, Yang I, Taylor BR, Hemming AW, Langer B, Grant DR, Greig PD, Gallinger S: Recurrence after liver resection for hepatocellular carcinoma: risk factors, treatment, and outcomes. Surgery 2007;141:330-339.
22. Tateishi R, Shiina S, Yoshida H, Teratani T, Obi S, Yamashiki N, Yoshida H, Akamatsu M, Kawabe T, Omata M: Prediction of recurrence of hepatocellular carcinoma after curative ablation using three tumor markers. Hepatology 2006;44:1518-1527.